Abstract CT303: Safety and efficacy of Elisrasib (D3S-001), a next generation GDP-bound KRAS G12C inhibitor, as monotherapy or combination therapy with cetuximab in previously treated metastatic CRC and PDAC: Results from a phase 1/2 study
Year: 2026
Type: conference-abstract
Source: Cancer Research
Authors: Kanwal Pratap Raghav, Jun Zhang, Myung-Ah Lee, Jingdong Zhang, John Park, Yanqiao Zhang, Susana Rosello Keranen, Byoung Chul Cho, Herbert Ho Fung Loong, Cheng Chen, Huan Li, Shaonan Wang, Yandong Shen, Zifei Fan, Qian Chen, Hui Wang, Jing Zhang, George Zhi Jian Chen, Jayesh Desai, Antoine Hollebecque
Institutions: The University of Texas MD Anderson Cancer Center, Shanghai Jiao Tong University, Ruijin Hospital, Liaoning Cancer Hospital & Institute, The Catholic University of Korea Seoul St. Mary's Hospital, Catholic University of Korea, Macquarie University, Harbin Medical University, Hospital Clínico Universitario de Valencia, Yonsei University, Yonsei University Health System, Yonsei Cancer Hospital, Chinese University of Hong Kong, Peter MacCallum Cancer Centre, Institut Gustave Roussy
Language: English
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W7154703019